Seite auswählen

Pharmaceutical and chemical giant Bayer has a new cancer drug in the pipeline, for gastrointestinal tumours (Gist), which continue to grow in spite of standard therapy treatment. In the U.S., it is likely that the rubber-stamped approval will be sought immediately, as a remedy for advanced colorectal cancer. The FDA has already provided the group with a priority review of the application.

Bayer trusts that Regorafenib, the successor drug of Sorafenib, will see annual sales peak at up to EUR 500 million. There are further therapeutic fields to reach too, say Bayer, who see the revenue opportunities of the drug at about EUR 1 billion. Bayer works with U.S. pharmaceutical company Onyx in respect to the drug.

[ilink url=““] Link zur Quelle ([/ilink]